Register Login
Register to leave comments
  • News bot Aug. 12, 2026, 11:03 a.m.

    📋 ACUMEN PHARMACEUTICALS, INC. (ABOS) - Financial Results

    Filing Date: 2026-08-12

    Accepted: 2026-08-12 07:02:30

    Event Type: Financial Results

    Event Details:

    ACUMEN PHARMACEUTICALS, INC. (ABOS) Reports the reporting period Financial Results ACUMEN PHARMACEUTICALS, INC. (ABOS) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 53016
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 59674
      • Expect to report topline results for ALTITUDE
      • AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026
      • Two candidates nominated for development in Acumen’s Enhanced Brain Delivery™ (EBD™) program; lead clinical candidate IND filing for the EBD program targeted for mid
        • targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995
        • targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.About ALTITUDE-AD (Phase 2)Initiated in 2024
        • targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 5.32K 5.39K $-71.00 -1.32%
    Current Liabilities Accounts Payable 13.38K 13.38K $0.00 +0.00%
    Operating Expenses Loss From Operations -41.75K -53.70K $11.96K +22.26%
    Other Income Expense Interest Income 2.02K 2.17K $-160.00 -7.36%
    Other Income Expense Interest Expense -1.05K -2.16K $1.12K +51.64%
    Other Income Expense Net Loss -40.95K -53.45K $12.51K +23.39%
    Other Comprehensive Gain Loss Net Loss Per Share -0.68 -0.68 $0.00 +0.00%
    Cash Flows From Operating Activities Net Loss -53.45K -53.45K $0.00 +0.00%
    Changes In Operating Assets And Liabilities Prepaid Expenses Other Current Assets 71.00 1.71K $-1.64K -95.86%
    Changes In Operating Assets And Liabilities Accounts Payable 12.82K -3.54K $16.37K +461.78%
    Prepaid Expenses and Other Current Assets 5.32K 5.39K $-71.00 -1.32%
    Other Assets 263.00 350.00 $-87.00 -24.86%
    Accounts Payable 13.38K 13.38K $0.00 +0.00%
    Loss from Operations -32.56K -41.75K $9.19K +22.02%
    Interest Income 1.11K 2.02K $-904.00 -44.86%
    Interest Expense -1.09K -1.05K $-48.00 -4.59%
    Net Loss -32.72K -40.95K $8.23K +20.10%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ACUMEN PHARMACEUTICALS, INC.
    • Ticker Symbol: ABOS

Search

News categories